İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Published on by Academic Awards

Assist. Prof. Dr. İlhan Sabancılar | Molecular Oncology | Best Researcher Award

Bitlis Eren University | Turkey

Assist. Prof. Dr. İlhan Sabancılar is a biochemist and medical researcher at Bitlis Eren University, Turkey, whose work bridges biochemistry, molecular medicine, and pharmaceutical sciences. His research primarily focuses on the anticancer, antioxidant, antimicrobial, and anti-inflammatory properties of bioactive compounds, natural extracts, and nanomaterials. Assist. Prof. Dr. İlhan Sabancılar has contributed to the synthesis and biological evaluation of novel heterocyclic and aza-acyclic nucleoside derivatives, investigating their potential as therapeutic agents through molecular docking and cytotoxicity studies. His publications in journals such as Pharmaceuticals, Current Issues in Molecular Biology, and Reviews on Environmental Health reflect his expertise in oxidative stress, trace element biochemistry, and drug development. With 9 publications and 247 citations, he has established a growing scientific presence supported by multiple research projects on oxidative stress, viral inhibition, and cancer therapeutics. A member of the Turkish Biochemical Society and the Molecular Cancer Research Association, Assist. Prof. Dr. İlhan Sabancılar’s multidisciplinary approach and consistent research output position him as a promising scholar contributing significantly to the advancement of biomedical and biochemical sciences.

Profile: Scopus | Orcid | Google Scholar

Featured Publications

1. Unsal, V., Cicek, M., & Sabancilar, İ. (2021). Toxicity of carbon tetrachloride, free radicals and role of antioxidants. Reviews on Environmental Health, 36(2), 279–295.

2. Bilden, A., Sabancılar, İ., Yalçın Azarkan, S., Karadağlı, K., Kaya, S., Kahraman, M., & Çiçek, M. (2025). Investigating the therapeutic potential of crude leech saliva based on its anticancer, antioxidant, and anti-inflammatory effects. Current Issues in Molecular Biology, 47(5), 328.

3. Sabancilar, İ., Unsal, V., Demir, F., Toprak, G., & Pekkolay, Z. (2023). Does oxidative status affect serum sclerostin levels in patients with type 2 diabetes mellitus? Folia Medica, 65(1), 46–52.

4. Alhilal, M., Alhilal, S., Gomha, S. M., Farag, B., Sabancilar, İ., & Ouf, S. A. (2025). Biological evaluation and molecular docking studies of novel aza-acyclic nucleosides as putative antimicrobial, anticancer, and antioxidant agents. BMC Chemistry, 19(1), 255.

5. Muhammed Ayral, H. T., Toprak, S. F., Dedeoğlu, S., & Sabancılar, İ. (2021). Kronik Otitis Media’da Tiyol-Disülfid Homeostazının Değişikliği. Dicle Tıp Dergisi, 48(1), 197–204.

6. Toprak, G., Sabancılar, İ., Özcan, N., & Alkan, H. (2020). Total oxidant status (TOS), total antioxidant status (TAS), ferritin and vitamin D levels in patients with chronic hepatitis C. Microbiology and Infectious Diseases, 4(2), 1–4.

 

Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

Published on by Academic Awards

Dr. Richard Moore | Gynecologic Oncology | Leadership in Research Excellence Award

University of Rochester | United States

Dr. Richard Moore is a distinguished leader in gynecologic oncology, renowned for his pioneering research, academic excellence, and leadership in translational medicine. He earned degrees in mechanical and industrial engineering before pursuing biology and obtaining his MD from the University of Alberta. His postgraduate training at Eastern Virginia Graduate School of Medicine and fellowship at Brown University established his foundation in women’s oncology. Over his illustrious career, Dr. Richard Moore has held prestigious roles, including Director of the Molecular Therapeutics Laboratory and Center for Biomarkers and Emerging Technology at Brown University, and currently serves as Chief of Gynecologic Oncology and Director of the Targeted Therapeutics Laboratory for Gynecologic Cancers at the University of Rochester Medical Center. A tenured professor, he has contributed significantly to advancing targeted therapeutics, biomarker discovery, and patient-centered oncology care. His work has earned numerous awards, international recognition, and over 8,037 citations from 135 publications and an impressive h-index of 39.

Profile: Scopus

Featured Publications

  • OVARIO Investigators, & Moore, R. G. (2025). A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: Final analysis and overall survival results from OVARIO. Gynecologic Oncology.

  • NRG Oncology, & Moore, R. G. (2025). Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nature Medicine.

  • Moore, R. G., et al. (2025). First-line lenvatinib plus pembrolizumab versus chemotherapy for advanced endometrial cancer: A randomized, open-label, phase III trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.

  • Moore, R. G., et al. (2025). Endometrioid adenocarcinoma of the colon arising from rare malignant transformation of extra-gonadal endometrioma. Gynecologic Oncology Reports.

  • Moore, R. G., et al. (2025). Estrogen therapy in patients with gynecologic cancer: A survey of gynecologists and oncologists in the United States. Menopause.